Abstract
The therapeutic landscape for acute myeloid leukemia (AML) has changed dramatically with the approval of targeted agents, including venetoclax, midostaurin, gilteritinib, ivosidenib, and enasidenib, among others. However, older patients with AML continue to experience poorer outcomes and are in ongoing need of more effective and less toxic regimens. This review examines the efficacy of novel therapeutics and promising combination approaches to further improve outcomes in the treatment of patients with AML.
| Original language | English (US) |
|---|---|
| Article number | 101106 |
| Journal | Best Practice and Research: Clinical Haematology |
| Volume | 32 |
| Issue number | 4 |
| DOIs | |
| State | Published - Dec 2019 |
Keywords
- AML
- Acute myeloid leukemia
- CR
- Complete response
- FLT3
- IDH1/2
- Isocitrate dehydrogenase-1/2
- OS
- Overall survival
- fms-related tyrosine kinase 3
ASJC Scopus subject areas
- Oncology
- Clinical Biochemistry